NLS Pharmaceutics AG
NASDAQ:NLSP
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
CH |
NLS Pharmaceutics AG
NASDAQ:NLSP
|
6.1m USD | 0 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -164 697 976 | |
US |
Eli Lilly and Co
NYSE:LLY
|
789.2B USD | 28.2 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 20 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 1 026 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
356.5B USD | 6.1 | ||
US |
Merck & Co Inc
NYSE:MRK
|
324.3B USD | 7.5 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
191.4B GBP | 61.6 | ||
CH |
Roche Holding AG
SIX:ROG
|
184.3B CHF | 4.7 | ||
CH |
Novartis AG
SIX:NOVN
|
181.3B CHF | 4.8 | ||
US |
Pfizer Inc
NYSE:PFE
|
165.6B USD | 5.7 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.